RxDoctor Payments Data

Jean Paul Achkar, MD

Gastroenterology · Cleveland, OHNPI 1467417261

Payments from drug & device makers

$1,009in general payments, 2019–2025

Across 48 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$327
  • Johnson & Johnson$281
  • AbbVie$109
  • Nestle Healthcare Nutrition Inc.$99
  • Takeda Pharmaceuticals U.S.A., Inc.$84
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$37
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$1,009100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,009 in reported general payments places this provider in the 30th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$41,544
Medicare patients
246
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab169$4,752,906
Humira(Cf) PenAdalimumab94$1,012,464
Humira PenAdalimumab24$194,170
EntyvioVedolizumab21$186,717
HumiraAdalimumab13$87,960
XeljanzTofacitinib Citrate12$70,819
Mesalamine90$50,758
Adalimumab-Adaz(Cf) PenAdalimumab-Adaz14$29,102
Balsalazide Disodium39$9,542
Mesalamine ErMesalamine34$8,667
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine68$3,430
LoperamideLoperamide Hcl62$2,968
Omeprazole104$1,785
Budesonide DrBudesonide12$980
Dicyclomine Hcl45$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$281$4,752,906169 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$84$186,71721 claims
AbbVieHumira$109$87,96013 claims
PfizerXeljanz$327$70,81912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →